🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
What actually happened in that operating room
A quick refresher on why beta oscillations run the show
From continuous to adaptive, and what ADAPT-PD actually proved
The electrode identifier and the six-hour monopolar review
Awake versus asleep, and the physiology that moved out of the OR
The programming bottleneck is the real constraint
Follow the money: codes, batteries, and who eats the cost
The competitive set nobody in neuromodulation enjoys discussing
What the neural data will be worth once there is enough of it
Four things worth watching
Abstract
FDA approved the first commercial closed-loop DBS system for Parkinson’s in February 2025, built on Medtronic’s sensing platform. The article’s claim that the platform had roughly 40,000 implanted patients worldwide, and therefore constituted the largest deployed brain-computer-interface base by a wide margin, is not established by the sources reviewed.
The pivotal ADAPT-PD study enrolled 68 participants. Its primary performance criterion was met by 79 percent of participants in the single-threshold mode and 91 percent in the dual-threshold mode; the study did not establish the article’s stated 92 percent and 95 percent equivalence figures. Total electrical energy delivered fell by about 15 percent in single-threshold adaptive stimulation, while dual-threshold adaptive stimulation produced exploratory improvements in on-time without troublesome dyskinesia. The article’s claim that 98 percent elected to remain on adaptive stimulation is not supported by the reported study results.
Real-world implementation data is messier. In one consecutive series of 20 chronically stimulated patients offered adaptive mode, only 9 were eligible, 5 stayed on it, motor scores improved about 35 percent, and average quality-of-life scores got worse by 28 percent.
The binding constraint on this market is not algorithmic. Roughly 9 percent of Medicare beneficiaries with Parkinson’s saw a movement disorder specialist in a given year, about 40 percent saw only a primary care physician or nobody at all, and referral disparities by race and income have barely moved in two decades.
Adaptive stimulation lowers total electrical energy delivered, which extends battery life, which erodes the recurring generator-replacement revenue that has quietly subsidized this category. It is a share-gain product, not an average-revenue-per-patient product.
Competition for the advanced-Parkinson’s patient now includes subcutaneous levodopa infusion, apomorphine infusion, focused ultrasound subthalamotomy, and a stem cell therapy in Phase 3, which means a hospital capital decision is being weighed against a pharmacy benefit decision in the same twelve-minute clinic visit.
